Navigation Links
Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
Date:6/4/2008

HAE:TSX

MONTREAL, June 4 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announces that it has started processing plasma in its new fractionation facility for the production of its proprietary all-human fibrin sealant for pivotal Phase II/Phase III clinical trials, leading to commercial launch.

Haemacure has reached an important milestone this week with the commencement of plasma fractionation in its new manufacturing facility. Haemacure also confirms that it is on schedule and on budget to produce clinical material during the third quarter of 2008 and file an amendment to its existing IND with the U.S. Food and Drug Administration during the fourth quarter of 2008, in order to begin clinical trials in the first quarter of 2009.

The new fractionation facility incorporates the Hynetics(R) single-use bio-processing plastic containers technology, which has resulted in significant savings in capital expenditures and will also result in significant savings in operating costs, as compared to a stainless steel facility. The use of this technology also minimizes the risks of cross-contamination between production batches.

"Now that our fractionation facility is operational and that we have started processing plasma, Haemacure is truly engaged in its transformation from a development to a manufacturing company." said Joseph Galli, Chairman and CEO of Haemacure. "The upcoming availability of clinical material will enable Haemacure to pursue its clinical plans in hemostasis and to expand into additional indications, such as adhesion prevention." concluded Mr. Galli.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.


'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
3. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
4. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
5. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
6. Haemacure Reports on its annual general and special meeting of shareholders
7. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
8. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
9. Haemacure financing receives shareholder consent - Series B Warrants are amended
10. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... , ... The Global Wellness Summit (GWS), an annual conference for ... wellness, travel, spa and beauty in Europe. The organization asked its partner experts in ... and researchers - to forecast where wellness is headed in Europe. Predictions range from ...
(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the ... tool and as an orthogonal tool for RNAi hit validation. A key reason may ... guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , ...
(Date:5/31/2016)... ... , ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree ... 1986, where he graduated in the top ten percentile of his class. Dr. Ditta ... He has been a member in good standing for thirty years in the American ...
(Date:5/30/2016)... ... May 30, 2016 , ... As the CDC relaxes its stance on traditional ... to keep their households lice free. , According to a May 26 article ... keep kids in the classroom despite the fact that they may be harboring an ...
(Date:5/29/2016)... ... ... Whole Health Supply is happy to announce the favorable reception of its ... new style of nail clipper has a wider jaw opening that is useful for ... actual handle is 2.5mm thick to accommodate the cutting force. This is the maximum ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... , May 30, 2016 ... H1 2016" market research report with comprehensive information ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:5/27/2016)... 2016 Hutchison China MediTech ... on the highly lucrative global oncology and immunology ... potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) ... strategic partners. HCM,s profitable Chinese healthcare business continues ... expect progress of the mid-to-late-stage pipeline during 2016-17 ...
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
Breaking Medicine Technology: